uniQure NV (QURE) Reaches New 52-Week Low at $6.68
uniQure NV (NASDAQ:QURE)’s share price hit a new 52-week low on Wednesday . The company traded as low as $6.68 and last traded at $6.98, with a volume of 368,540 shares. The stock had previously closed at $7.00.
A number of equities analysts recently weighed in on the company. Chardan Capital reissued a “buy” rating on shares of uniQure NV in a research note on Monday, July 18th. Piper Jaffray Cos. restated a “buy” rating on shares of uniQure NV in a research report on Thursday, June 30th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $23.00 price objective on shares of uniQure NV in a research report on Wednesday, June 15th. WallachBeth Capital decreased their price objective on uniQure NV from $60.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, June 15th. Finally, Cowen and Company restated a “buy” rating on shares of uniQure NV in a research report on Tuesday, June 14th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $30.80.
The company’s market capitalization is $177.21 million. The firm has a 50 day moving average of $8.15 and a 200-day moving average of $12.45.
uniQure NV (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 31st. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.10. Equities research analysts predict that uniQure NV will post ($3.44) earnings per share for the current year.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.